−3.8%
since Oct 2
The idea
I believe personalized medicine, treatments built around a patient's own biology, becomes a normal part of medicine over the next decade or two, not just a Covid moment. Since no one can pick which specific drug wins, most of this basket sits in the picks-and-shovels layer: sequencing, lab tools, and manufacturing suppliers who get paid regardless of whose trial succeeds. Smaller slices go to the platform makers and diagnostics companies actually testing that thesis, with big pharma partners for ballast and cash held on the side.
What it owns
- Suppliers of instruments, reagents, and analytical tools that enable tumor profiling and therapy design across the personalized medicine field. · DanaherIt supplies the bioprocessing and diagnostics tools every genetic medicine maker relies on, collecting revenue across the sector regardless of individual drug outcomes., Thermo Fisher ScientificIt provides instruments, reagents, and contract manufacturing across genetic medicine programs, earning fees from sector-wide growth in R&D and manufacturing., IlluminaIt makes the sequencers that read tumor genomes used to design custom vaccines, functioning as a critical infrastructure point for the entire approach., Agilent TechnologiesIt sells analytical and quality-control instruments used daily by drug developers and diagnostics labs, capturing sector growth without betting on individual therapies., Twist BioscienceIt manufactures synthetic DNA used in vaccine design, gene editing, and sequencing panels, functioning as a raw ingredient for the personalized medicine field., 10x GenomicsIt provides single-cell and spatial analysis tools researchers use to understand tumors and immune responses, enabling the science that drives personalized therapy design.26%
- Large pharmaceutical companies with direct stakes in personalized medicine through partnerships, approved therapies, or committed pipeline investment. · Merck & CoIt partners with Moderna on a personalized cancer vaccine paired with its Keytruda franchise, giving it exposure to custom immunotherapy without depending entirely on the approach., AstraZenecaIt has moved deeper into targeted cancer drugs matched to tumor genetics, offering steady exposure to precision oncology adoption., NovartisIt already commercializes gene therapies and RNA-based medicines like Zolgensma and Leqvio, demonstrating that large pharmaceutical companies can profitably scale genetic medicines., SanofiIt committed billions to mRNA vaccines and immunology after acquiring Translate Bio, explicitly betting that the mRNA platform extends beyond infectious disease.22%
- Companies developing core technologies like mRNA, RNA interference, CRISPR, and gene editing with multiple approved or late-stage programs. · ModernaIt is advancing individualized cancer vaccines in late-stage trials and represents the bet that mRNA becomes a platform beyond infectious disease., BioNTechIt was founded on individualized cancer immunotherapy and holds a broad oncology pipeline with substantial cash to advance personalized vaccine programs., Alnylam PharmaceuticalsIt holds multiple approved RNA-silencing drugs and a pipeline validating that programmable genetic medicine is a commercial business at scale., CRISPR TherapeuticsIt has Casgevy approved as the first CRISPR medicine on market with a pipeline extending gene editing into cancer and heart disease., Arcturus TherapeuticsIt is developing self-amplifying mRNA that works at lower doses with an approved Covid vaccine and partnered programs advancing the platform.20%
- Suppliers of components, materials, and equipment needed to manufacture and deliver genetic medicines at scale. · West Pharmaceutical ServicesIt manufactures the stoppers, seals, and delivery components for injectable biologics including mRNA vaccines, earning more volume as approved genetic medicines expand., RepligenIt supplies filtration and purification equipment used repeatedly in biologics and mRNA manufacturing, with demand tied to bioprocessing capacity expansion., AvantorIt distributes chemicals, single-use kits, and supplies for biopharma production, with revenue tracking sector activity rather than individual drug outcomes., Maravai LifeSciencesIt makes CleanCap and other essential inputs for mRNA manufacturing, representing the most direct supplier bet on mRNA becoming a standard drug class.13%
- Companies providing tests and data analytics that identify patients for personalized treatment and measure therapy response. · NateraIts Signatera test detects tumor DNA fragments in blood to identify candidates for personalized vaccines and measure response., Guardant HealthIt profiles cancer from blood draws to identify patients for personalized treatment, acting as the critical first step in matching therapy to tumor., Tempus AIIt provides software that turns genomic and clinical data into treatment recommendations, the analytical layer needed to scale personalized medicine beyond academic centers.11%
- Cash8%